Pharma

Pharma Overview

We are amongst the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (“CDMO”) industry in India in terms of revenue. With over two decades of experience in manufacturing both solid and liquid pharmaceutical dosage forms and significant experience in providing specialized capabilities, including, high potency, controlled substances and low-solubility.

  • Comprehensive CDMO Services: The company offers a wide range of Contract Development and Manufacturing Organization (CDMO) services, spanning from product discovery to commercial manufacturing. These services comply with current Good Manufacturing Practices (GMP), emphasizing safety, efficacy, and cost-effectiveness.

  • Market Share: In Fiscal 2020, the company held a market share of approximately 1.5% in terms of revenue within the domestic formulations CDMO industry.

  • Diverse Portfolio: Besides CDMO services, the company is involved in selling its own branded products in trade generics and over-the-counter (OTC) markets. Additionally, it exports generic products to multiple countries.

  • Rising Chronic Diseases: The prevalence of chronic diseases in India, particularly in therapeutic categories like anti-diabetic, cardiovascular, neuropsychiatry, and respiratory, has been on the rise. These conditions often require multi-drug therapy, involving the use of two or more drugs for single or multiple chronic conditions in individuals.

  • Growing Importance of Multi-Drug Therapy: Multi-drug therapy has become increasingly significant in the healthcare sector, contributing to the growth of pharmaceutical consumption. The company has expertise in developing and manufacturing generic fixed dose combinations, with a focus on launching new complex generic products in the chronic therapeutic category linked to lifestyle-related disorders.

  • Strategic Focus: The company’s strategic focus is on meeting the demand for complex generic products in chronic therapeutic areas. This aligns with the evolving landscape of healthcare where multi-drug therapy plays a crucial role in addressing lifestyle-related disorders.

  • Global Reach: In addition to the domestic market, the company exports generic products to several countries, indicating a global presence and market diversification.

  • Quality Standards: Adherence to GMP underscores the company’s commitment to maintaining high-quality standards throughout the product development and manufacturing processes.

  • Revenue Streams: The company’s revenue streams are diversified, encompassing CDMO services, sales of branded products, and export of generic products, providing a robust and resilient business model.

  • We have three distinct strategic business verticals (“SBVs”):  (i) CDMO Services and Products; (ii) Domestic Trade Generics and over-the-counter (“OTC”) Brands; and (iii) Exports.